Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Payables (2016 - 2025)

Dexcom (DXCM) has disclosed Payables for 16 consecutive years, with $1.9 billion as the latest value for Q4 2025.

  • On a quarterly basis, Payables fell 30.31% to $1.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 billion, a 30.31% decrease, with the full-year FY2025 number at $1.9 billion, down 30.31% from a year prior.
  • Payables was $1.9 billion for Q4 2025 at Dexcom, up from $1.2 billion in the prior quarter.
  • In the past five years, Payables ranged from a high of $2.8 billion in Q4 2024 to a low of $124.2 million in Q3 2023.
  • A 5-year average of $1.2 billion and a median of $1.2 billion in 2025 define the central range for Payables.
  • Peak YoY movement for Payables: soared 107.32% in 2024, then crashed 30.31% in 2025.
  • Dexcom's Payables stood at $573.0 million in 2021, then soared by 34.83% to $772.6 million in 2022, then skyrocketed by 74.15% to $1.3 billion in 2023, then surged by 107.32% to $2.8 billion in 2024, then plummeted by 30.31% to $1.9 billion in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Payables are $1.9 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q2 2025).